Study #2023-0420
Phase 1/2 study of IDP 023 as a single agent and in combination with antibody therapies in patients with advanced Hematologic cancers.
MD Anderson Study Status
Enrolling
Treatment Agent
IDP-023, Cyclophosphamide, Fludarabine, Mesna, Interleukin-2, Rituximab, Daratumumab, Isatuximab
Description
This is an open label, Phase 1/2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combination with or without interleukin-2 (IL-2), and with or without isatuximab, daratumumab or rituximab to evaluate the safety, tolerability and preliminary antitumor activity in patients with advanced hematologic cancers.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
NHL, Multiple Myeloma, Blood Cancer, Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma
Study phase:
Physician name:
Krina Patel
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-888-604-0639
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.